|
Melioidosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The area under receiver operating characteristic curve (AUROCC) to discriminate melioidosis cases from healthy donors was highest for anti-Hcp1 IgG (0.92) compared to anti-Hcp1 IgA or IgM.
|
31562344 |
2019 |
|
Melioidosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated by enzyme-linked immunosorbent assay (ELISA) that a hemolysin-coregulated protein (Hcp1) is a promising target for serodiagnosis of melioidosis.
|
29848565 |
2018 |
|
Melioidosis
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We evaluated rapid ELISAs using crude antigens, purified OPS and Hcp1 to measure antibody levels in three sets of sera: (i) 419 serum samples from melioidosis patients, Thai and U.S. healthy donors, (ii) 120 serum samples from patients with other bacterial infections, and (iii) 423 serum samples from 200 melioidosis patients obtained upon admission and at 12 and 52 weeks post-recovery.
|
28358816 |
2017 |
|
Melioidosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The detection of anti-Hcp1 antibodies in patients' sera indicating the presence of B. pseudomallei highlights the potential of Hcp1 to be further developed as a serodiagnostic marker for melioidosis.
|
25616255 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Consistent with the biological effect of other PDE4 and PDE7 inhibitors, BC54 displays potent anti-inflammatory properties and is superior to a combination of rolipram (a PDE4 inhibitor) and BRL50481 (a PDE7A inhibitor) for inducing apoptosis in chronic lymphocytic leukemia (CLL) cells.
|
28867658 |
2017 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have studied the effects of a novel PDE7 inhibitor (PDE7i) treatment on mice with experimental autoimmune encephalomyelitis (EAE) a model of multiple sclerosis (MS) and compared it with another PDE7i.
|
28007551 |
2017 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
This combination of an advantageous effect on the immune response and an enhancement of repair, plus demonstration of its activity on adult human OPCs, leads us to propose dual PDE7-GSK3 inhibition, and specifically VP3.15, as a neuroprotective and neuroreparative disease-modifying treatment for MS.
|
28256546 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The increase in PDE7B expression and PDE7 inhibitor-promoted apoptosis implicates PDE7B as a drug target in CLL.
|
19033455 |
2008 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this article we review the literature on PDE7A and explore the possibility that selective small molecule inhibitors of this enzyme family could provide a novel approach to alleviate the inflammation that is associated with many inflammatory diseases including asthma, chronic obstructive pulmonary disease, atopic dermatitis, psoriasis, lupus, rheumatoid arthritis and multiple sclerosis.
|
17020529 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
WSU-CLL PDE7A was also up-regulated by a novel specific inhibitor (IC242), which inhibits PDE7A from WSU-CLL cells with an IC50 value of 0.84 microM.
|
11812656 |
2002 |
|
Neurodegenerative Disorders
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Phosphodiesterase 7 (PDE7) is a key enzyme involved in the degradation of intracellular levels of cyclic adenosine 3', 5'-monophosphate in different cell types; however, little is known regarding its role in neurodegenerative diseases, and specifically in Parkinson's disease.
|
31473904 |
2020 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we show new therapeutic effects of the PDE7 inhibitor, confirming S14 as a potential therapeutic drug for AD.
|
29458418 |
2018 |
|
Rheumatoid Arthritis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Anti-VCP1 were detected in 44% of RA patients; anti-VCP2 in 52%; anti-HCP1 in 46% and anti-HCP2 in 63%.
|
28826660 |
2018 |
|
Neurodegenerative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Given the interest in the development of new drugs for MS, including PDE7i as anti-inflammatory drugs, it is important to study the role played by PDE7 in neurodegenerative diseases with inflammatory component to better understand the beneficial and detrimental effects of a future therapy.
|
28007551 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
|
25955017 |
2015 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
|
25955017 |
2015 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease is associated with changes in PDE4, PDE7, and PDE8 expression in the brain.
|
23129425 |
2012 |
|
Chronic Obstructive Airway Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the present study, PDE 4 and PDE 7 subtype messenger ribonucleic acid (mRNA) transcripts in CD4 and CD8 lymphocytes from healthy (n=10) and asthmatic (n=10) subjects and polymorphonuclear neutrophils (PMNs) and CD8 lymphocytes obtained from healthy (n=10) and chronic obstructive pulmonary disease (COPD) (n=7) subjects were identified and quantified.
|
16427796 |
2007 |
|
Rheumatoid Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this article we review the literature on PDE7A and explore the possibility that selective small molecule inhibitors of this enzyme family could provide a novel approach to alleviate the inflammation that is associated with many inflammatory diseases including asthma, chronic obstructive pulmonary disease, atopic dermatitis, psoriasis, lupus, rheumatoid arthritis and multiple sclerosis.
|
17020529 |
2006 |
|
Chronic Obstructive Airway Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this article we review the literature on PDE7A and explore the possibility that selective small molecule inhibitors of this enzyme family could provide a novel approach to alleviate the inflammation that is associated with many inflammatory diseases including asthma, chronic obstructive pulmonary disease, atopic dermatitis, psoriasis, lupus, rheumatoid arthritis and multiple sclerosis.
|
17020529 |
2006 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
As treatment with the methylxanthine theophylline, a nonspecific PDE inhibitor, induces apoptosis in leukemic cells from patients with the B-lineage malignancy chronic lymphocytic leukemia (CLL), we sought to determine if PDE7A was a target of theophylline therapy in such cells.
|
11812656 |
2002 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
As treatment with the methylxanthine theophylline, a nonspecific PDE inhibitor, induces apoptosis in leukemic cells from patients with the B-lineage malignancy chronic lymphocytic leukemia (CLL), we sought to determine if PDE7A was a target of theophylline therapy in such cells.
|
11812656 |
2002 |
|
Parkinson Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we have used in vitro and in vivo models of Parkinson's disease to study the regulation of PDE7 protein levels.
|
31473904 |
2020 |
|
Glanders and melioidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our current work, we evaluated the protective efficacy of CLH001 against glanders and melioidosis in the more disease-resistant C57BL/6 mouse strain.
|
31306423 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Murine (CT26) and human (HCP-1) CRC cell lines were treated with CM from lipopolysaccharide (LPS)-activated murine macrophages.
|
29293549 |
2018 |